Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Talking to a computer could reveal if psychosis is bipolar or schizophrenia

NCT ID NCT05384392

Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 217 people after their first psychotic episode to see if language patterns and blood markers can predict whether they will develop bipolar disorder or schizophrenia. Participants give a recorded interview and blood sample at the start, then are followed for two years. The goal is to speed up accurate diagnosis and improve treatment choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors quickly identify the right type of psychosis, leading to faster, more personalized treatment and fewer relapses.
What could go wrong
This is an observational study, not a treatment trial. The findings may not be definitive or widely applicable, and it will take years to see if the biomarkers are reliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 217 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with a first episode of psychosis, * Aged between 15 and 30 years, * Able to consent and having signed a consent form (parental consent for minors). Exclusion Criteria: * Introduction or increase of antipsychotic and/or antidepressant and/or thymoregulatory treatment in the last month, * Mother tongue other than French, * Psychotic episode due to an organic disorder, * Psychotic episode induced by the use or withdrawal of toxic substances with severe dependence , * Intellectual deficit, * Chronic inflammatory disease, * Immunomodulatory treatment, * Contraindication to MRI, * Pregnant or breastfeeding woman, * Patient under court protection, guardianship, curatorship or deprived of liberty.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for First episode psychosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder Schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

First episode psychosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dr Anne SAUVAGET

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • Dr Dominique DRAPIER

    RECRUITING

    Rennes, 35703, France

  • Dr Efflam BREGEON

    RECRUITING

    Angers, 49033, France

  • Dr Florian STEPHAN

    RECRUITING

    Brest, 29609, France

  • Dr Vincent CAMUS

    RECRUITING

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.